Vimarsana
Biggest News Aggregation in the World

Page 43 - Platform Technology News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Platform Technology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Platform Technology Today - Breaking & Trending Today

Sinoveda's Patented Pharmaceutical Platform Technology Is Revolutionizing Health - Vimarsana News

Sinoveda's Patented Pharmaceutical Platform Technology Is Revolutionizing Health

/PRNewswire/ -- Sinoveda is a revolutionary health-science brand that is changing the way consumers can approach health and wellness. As one of seven Canadian...

A Pain Relief Option That Is Only Possible When East Meets West - Vimarsana News

A Pain Relief Option That Is Only Possible When East Meets West

/PRNewswire/ -- The health and wellness industry is currently suffering from an excess of pain relief options. From dangerously strong NSAIDs to highly...

Sinoveda's Patented Pharmaceutical Platform Technology Is Revolutionizing Health - Vimarsana News

Sinoveda's Patented Pharmaceutical Platform Technology Is Revolutionizing Health

/PRNewswire/ -- Sinoveda is a revolutionary health-science brand that is changing the way consumers can approach health and wellness. As one of seven Canadian...

Synaffix Named 'Biotech Company of the Year' at the LSX European Lifestars Awards - Vimarsana News

Synaffix Named 'Biotech Company of the Year' at the LSX European Lifestars Awards

AMSTERDAM, Nov. 16, 2022 /PRNewswire/ -- Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug

Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update - Vimarsana News

Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update

14.11.2022 - Continued Progress in Pepinemab Oncology and Neurology Clinical ProgramsPromising initial responses in Phase 1b/2 open-label KEYNOTE B84 study of pepinemab with KEYTRUDA in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patient ...